Homepage Top Section1

The early-stage trial will study safety, pharmacokinetics, and pharmacodynamics of VE-1902 in 100-120 participants. The blood thinner is the first PRrecision Oral AntiCoagulant (PROAC) of the US-based pharma

MeiraGTx has five programs in clinical development and a pipeline of preclinical and research programs. As part of a worldwide collaboration and license agreement, the partnership will develop,

The breakthrough therapy designation has been granted for V114 to prevent invasive pneumococcal disease (IPD) caused by the vaccine serotypes in pediatric patients aged between six weeks and

The AEGIS-CKD study of Feraccru was a phase 3 randomized, placebo-controlled, double-blind trial. Compared to placebo, Shield Therapeutics’ ferric iron therapy showed superiority in changing haemoglobin (Hb) levels

The trial is the second phase 1 safety clinical study of XF-73, which evaluated its potential to cause dermal irritation when applied topically. Destiny Pharma has designed the

The acquired rights will cover all potential indications in the hospital setting for the administration of inhaled AirNOvent at up to 80 parts per million. One of the

The second indication of Rubraca has been approved as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

An oral porcupine inhibitor, RXC004 has been designed to target the Wnt signaling pathway. The early-stage trial of the small molecule drug was temporarily stopped in March 2018

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet